Literature DB >> 23263003

Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012.

Fei Zhao1, Gang Liu, Jiang Wu, Bin Cao, Xiaoxia Tao, Lihua He, Fanliang Meng, Liang Zhu, Min Lv, Yudong Yin, Jianzhong Zhang.   

Abstract

Macrolide resistance rates of Mycoplasma pneumoniae in the Beijing population were as high as 68.9%, 90.0%, 98.4%, 95.4%, and 97.0% in the years 2008 to 2012, respectively. Common macrolide-resistant mobile genetic elements were not detected with any isolate. These macrolide-resistant isolates came from multiple clones rather than the same clone. No massive aggregation of a particular clone was found in a specific period.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23263003      PMCID： PMC3591905          DOI： 10.1128/AAC.02060-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Community-acquired pneumonia in children.

Authors:  Kenneth McIntosh
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

2.  Sensitive detection of Mycoplasma pneumoniae in human respiratory tract samples by optimized real-time PCR approach.

Authors:  Roger Dumke; Nicol Schurwanz; Matthias Lenz; Markus Schuppler; Christian Lück; Enno Jacobs
Journal:  J Clin Microbiol       Date:  2007-05-30       Impact factor: 5.948

3.  Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia.

Authors:  Miyuki Morozumi; Satoshi Iwata; Keiko Hasegawa; Naoko Chiba; Reiko Takayanagi; Keita Matsubara; Eiichi Nakayama; Keisuke Sunakawa; Kimiko Ubukata
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

4.  Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.

Authors:  Yang Liu; Xinyu Ye; Hong Zhang; Xiaogang Xu; Wanhua Li; Demei Zhu; Minggui Wang
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

5.  Multiple-locus variable-number tandem-repeat analysis of 201 Mycoplasma pneumoniae isolates from Beijing, China, from 2008 to 2011.

Authors:  Fei Zhao; Gang Liu; Bin Cao; Jiang Wu; Yixin Gu; Lihua He; Fanliang Meng; Liang Zhu; Yudong Yin; Min Lv; Jianzhong Zhang
Journal:  J Clin Microbiol       Date:  2012-12-05       Impact factor: 5.948

6.  Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan.

Authors:  Mayumi Matsuoka; Mitsuo Narita; Norio Okazaki; Hitomi Ohya; Tsutomu Yamazaki; Kazunobu Ouchi; Isao Suzuki; Tomoaki Andoh; Tsuyoshi Kenri; Yuko Sasaki; Atsuko Horino; Miharu Shintani; Yoshichika Arakawa; Tsuguo Sasaki
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 7.  New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections.

Authors:  Ken B Waites; Mitchell F Balish; T Prescott Atkinson
Journal:  Future Microbiol       Date:  2008-12       Impact factor: 3.165

8.  Molecular mechanisms of macrolide resistance in clinical isolates of Mycoplasma pneumoniae from China.

Authors:  Deli Xin; Zuhuang Mi; Xu Han; Ling Qin; Jing Li; Tianli Wei; Xiaogeng Chen; Shaojie Ma; Ancun Hou; Gui Li; Dawei Shi
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

9.  Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis.

Authors:  O Peuchant; A Ménard; H Renaudin; M Morozumi; K Ubukata; C M Bébéar; S Pereyre
Journal:  J Antimicrob Chemother       Date:  2009-05-09       Impact factor: 5.790

10.  Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae.

Authors:  T S Lucier; K Heitzman; S K Liu; P C Hu
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191
View more
  63 in total

1.  In vitro subminimum inhibitory concentrations of macrolide antibiotics induce macrolide resistance in Mycoplasma pneumoniae.

Authors:  G Ou; Y Liu; Y Tang; X You; Y Zeng; J Xiao; L Chen; M Yu; M Wang; C Zhu
Journal:  Hippokratia       Date:  2015 Jan-Mar       Impact factor: 0.471

2.  First report of macrolide resistance in a Mycoplasma pneumoniae isolate causing community-acquired pneumonia in Spain.

Authors:  Juan de Dios Caballero; Rosa del Campo; María Del Carmen Mafé; María Gálvez; Mario Rodríguez-Domínguez; Rafael Cantón; María Antonia Meseguer; José Manuel Hermida
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

Review 3.  Atypical Pneumonia: Updates on Legionella, Chlamydophila, and Mycoplasma Pneumonia.

Authors:  Lokesh Sharma; Ashley Losier; Thomas Tolbert; Charles S Dela Cruz; Chad R Marion
Journal:  Clin Chest Med       Date:  2016-12-24       Impact factor: 2.878

4.  Study of Two Separate Types of Macrolide-Resistant Mycoplasma pneumoniae Outbreaks.

Authors:  Yingshuo Wang; Qian Ye; Dehua Yang; Zhimin Ni; Zhimin Chen
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

Review 5.  Mycoplasma pneumoniae from the Respiratory Tract and Beyond.

Authors:  Ken B Waites; Li Xiao; Yang Liu; Mitchell F Balish; T Prescott Atkinson
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

6.  Low rate of macrolide resistance in Mycoplasma pneumoniae strains in Germany between 2009 and 2012.

Authors:  Roger Dumke; Christian Lück; Enno Jacobs
Journal:  Antimicrob Agents Chemother       Date:  2013-05-06       Impact factor: 5.191

7.  Epidemiology and Molecular Characteristics of Mycoplasma pneumoniae During an Outbreak of M. pneumoniae-associated Stevens-Johnson Syndrome.

Authors:  Louise K Francois Watkins; Daniel Olson; Maureen H Diaz; Xia Lin; Alicia Demirjian; Alvaro J Benitez; Jonas M Winchell; Christine C Robinson; Kirk A Bol; Mary P Glodé; Samuel R Dominguez; Lisa A Miller; Preeta K Kutty
Journal:  Pediatr Infect Dis J       Date:  2017-06       Impact factor: 2.129

8.  A randomized, open, multicenter clinical study on the short course of intravenous infusion of 750 mg of levofloxacin and the sequential standard course of intravenous infusion/oral administration of 500 mg of levofloxacin for treatment of community-acquired pneumonia.

Authors:  Tiemei Zhao; Liang-An Chen; Ping Wang; Guizhen Tian; Feng Ye; Huili Zhu; Bei He; Baiying Zhang; Changzhou Shao; Zhijun Jie; Xiwen Gao; Dongxia Wang; Weidong Song; Zhijie Pan; Jin Chen; Xingyi Zhang; Zhancheng Gao; Ping Chen; Youning Liu
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

9.  Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program.

Authors:  K B Waites; A Ratliff; D M Crabb; L Xiao; X Qin; R Selvarangan; Y-W Tang; X Zheng; J Dien Bard; T Hong; M Prichard; E Brooks; S Dallas; L Duffy; E Mixon; K B Fowler; T P Atkinson
Journal:  J Clin Microbiol       Date:  2019-10-23       Impact factor: 5.948

Review 10.  Resistance to Macrolide Antibiotics in Public Health Pathogens.

Authors:  Corey Fyfe; Trudy H Grossman; Kathy Kerstein; Joyce Sutcliffe
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.